Free Trial

MyMD Pharmaceuticals (MYMD) Competitors

MyMD Pharmaceuticals logo
$0.12 -0.02 (-11.52%)
As of 07/25/2025

MYMD vs. PTPI, TRVN, PBLA, HEPA, BPTSY, SYRS, VIRX, NCNA, VINC, and CAPS

Should you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Petros Pharmaceuticals (PTPI), Trevena (TRVN), Panbela Therapeutics (PBLA), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Syros Pharmaceuticals (SYRS), Viracta Therapeutics (VIRX), NuCana (NCNA), Vincerx Pharma (VINC), and Capstone Therapeutics (CAPS). These companies are all part of the "pharmaceutical products" industry.

MyMD Pharmaceuticals vs. Its Competitors

Petros Pharmaceuticals (NASDAQ:PTPI) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Petros Pharmaceuticals' return on equity of -78.22% beat MyMD Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
MyMD Pharmaceuticals N/A -179.05%-108.14%

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MyMD Pharmaceuticals has lower revenue, but higher earnings than Petros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.19-$8.16M-$60.870.00
MyMD PharmaceuticalsN/AN/A-$4MN/AN/A

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
MyMD Pharmaceuticals Neutral

Petros Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.

Summary

Petros Pharmaceuticals beats MyMD Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Get MyMD Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYMD vs. The Competition

MetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$277K$19.95M$5.69B$9.50B
Dividend YieldN/AN/A4.58%4.01%
P/E RatioN/AN/A28.1020.05
Price / SalesN/A22.04432.4490.07
Price / CashN/AN/A36.2258.56
Price / Book0.020.028.665.87
Net Income-$4M-$15.34M$3.25B$258.55M
7 Day PerformanceN/A11.11%4.23%3.74%
1 Month Performance-15.12%-8.83%10.52%11.75%
1 Year Performance-93.92%-47.22%34.41%18.03%

MyMD Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MYMD
MyMD Pharmaceuticals
N/A$0.12
-11.5%
N/A-92.9%$277KN/A0.006Gap Down
High Trading Volume
PTPI
Petros Pharmaceuticals
N/A$0.03
-1.7%
N/A-99.7%$913K$5.11M-0.0120Gap Down
TRVN
Trevena
1.1673 of 5 stars
$0.91
flat
$5.00
+449.5%
-84.0%$873K$443K-0.0240
PBLA
Panbela Therapeutics
0.2989 of 5 stars
$0.16
-1.3%
N/A-53.1%$767KN/A0.006
HEPA
Hepion Pharmaceuticals
0.1279 of 5 stars
$0.06
+20.0%
N/A-99.9%$656KN/A-0.0120Gap Up
BPTSY
Biophytis
N/A$1.81
flat
N/AN/A$634KN/A0.0030Gap Up
SYRS
Syros Pharmaceuticals
4.1419 of 5 stars
$0.02
flat
$3.33
+16,566.7%
-99.8%$537K$386K-0.01120News Coverage
Upcoming Earnings
Gap Down
VIRX
Viracta Therapeutics
2.5622 of 5 stars
$0.01
flat
$1.75
+17,793.7%
N/A$389KN/A-0.0120
NCNA
NuCana
3.318 of 5 stars
$0.05
-0.2%
$25.00
+47,159.0%
-98.3%$320KN/A-0.0130Gap Up
High Trading Volume
VINC
Vincerx Pharma
2.4891 of 5 stars
$0.05
-9.3%
$40.00
+77,269.4%
-99.6%$271KN/A0.0060Gap Down
CAPS
Capstone Therapeutics
N/A$1.69
+5.6%
N/AN/A$270K$44.88M0.0038

Related Companies and Tools


This page (NASDAQ:MYMD) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners